Achillion Pharmaceuticals, Inc. ACHN announced completion of enrollment target in two phase II studies evaluating its lead pipeline candidate, ACH-4471. Both the studies, a six-month study and a 12-month study, are evaluating ACH-4471 in C3 glomerulopathy (C3G), a devastating disease affecting the kidney.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,